The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
Open accessAbstract
The clinical usefulness of trastuzumab (Herceptin; Genentech, San Francisco, CA) in breast cancer treatment is limited by the rapid development of resistance. We previously reported that IGF‐I signaling confers resistance to the growth‐inhibitory actions of trastuzumab in a model system, but the underlying molecular mechanism remains unknown. We used SKBR3/neo cells (expressing few IGF‐I receptors) and SKBR3/IGF‐IR cells (overexpressing IGF‐I receptor) as our experimental model. IGF‐I antagonized the trastuzumab‐induced increase in the level of the Cdk inhibitor p27 Kip1. This resulted in decreased association of p27 Kip1 with Cdk2, restoration of Cdk2 activity and attenuation of cell‐cycle arrest in G 1 phase, all of which had been induced by trastuzumab treatment in SKBR3/IGF‐IR cells. We also found that the decrease in p27 Kip1 induced by IGF‐I was accompanied by an increase in expression of Skp2, which is a ubiquitin ligase for p27 Kip1, and by increased Skp2 association with p27 Kip1. A specific proteasome inhibitor (LLnL) completely blocked the ability of IGF‐I to reduce the p27 Kip1 protein level, while IGF‐I increased p27 Kip1 ubiquitination. This suggests that the action of IGF‐I in conferring resistance to trastuzumab involves targeting of p27 Kip1 to the ubiquitin/proteasome degradation machinery. Finally, specific inhibitors of MAPK and PI3K suggest that the IGF‐I‐mediated reduction in p27 Kip1 protein level by increased degradation predominantly involves the PI3K pathway. Our results provide an example of resistance to an antineoplastic therapy that targets one tyrosine kinase receptor by increased signal transduction through an alternative pathway in a complex regulatory network. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Protean PTEN: Form and Function
Waite, K. A., & Eng, C. (2002) · The American Journal of Human Genetics · doi:10.1086/340026 · Cited by 457
Growth factor‐dependent signaling and cell cycle progression
Jones, S. M., & Kazlauskas, A. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02113-5 · Cited by 124
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Self-citationDissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Metadata
- Authors
- Lu, Y., Zi, X., & Pollak, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2003-10-28
- Volume
- 108
- Issue
- 3
- Pages
- 334-341
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2033595975
- Cited by
- 208
- References
- 5
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.